Cohbar, Inc. (CWBR)

Trade CWBR now with
1/11/2021 9:14:12 AM CohBar Signs Non-Clinical Evaluation Agreement With NIAID To Evaluate Potential Of CB5064 Analogs
8/24/2020 9:08:19 AM CohBar Announces First Subjects Dosed In Its Phase 1b Clinical Trial For CB4211 Under Development For NASH And Obesity
7/7/2020 9:08:39 AM CohBar Resumes Phase 1b Stage Of Its Phase 1a/1b Clinical Trial Of CB4211
4/22/2019 9:33:15 AM CohBar Appoints David Greenwood To Its Board
12/10/2018 4:09:35 PM CohBar Appoints Philippe Calais As Interim CEO
8/14/2018 4:04:26 PM CohBar Q2 Loss Per Share $0.08 Vs. $0.05 Last Year
6/7/2018 9:00:52 AM CohBar Appoints Philippe Calais To Its Board